Aron Popovtzer

Prof. Dr. Aron Popovtzer


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in International Journal of Radiation Oncology, Biology, Physics
Verified
Journal Article
Open access
APAron Popovtzer
Aron Popovtzer
ERE. Rosenfeld
E. Rosenfeld
AMA. Mizrachi
A. Mizrachi
SBS.R. Bellia
S.R. Bellia
RBR. Ben-Hur
R. Ben-Hur
YKY. Keisari
Y. Keisari
Our purpose was to report the feasibility and safety of diffusing alpha-emitter radiation therapy (DaRT), which entails the interstitial implantation of a novel alpha-emitting brachytherapy source, for the treatment of locally advanced and recurrent squamous cancers of the skin and head and neck. This prospective first-in-human, multicenter clinical study evaluated 31 lesions in 28 patients. The primary objective was to determine the feasibility and safety of this approach, and the secondary objectives were to evaluate the initial tumor response and local progression-free survival. Eligibility criteria included all patients with biopsy-proven squamous cancers of the skin and head and neck with either primary tumors or recurrent/previously treated disease by either surgery or prior external beam radiation therapy; 13 of 31 lesions (42%) had received prior radiation therapy. Toxicity was evaluated according to the Common Terminology Criteria for Adverse Events version 4.03. Tumor response was assessed at 30 to 45 days at a follow-up visit using the Response Evaluation Criteria in Solid Tumors, version 1.1. Median follow-up time was 6.7 months. Acute toxicity included mostly local pain and erythema at the implantation site followed by swelling and mild skin ulceration. For pain and grade 2 skin ulcerations, 90% of patients had resolution within 3 to 5 weeks. Complete response to the Ra-224 DaRT treatment was observed in 22 lesions (22/28; 78.6%); 6 lesions (6/28, 21.4%) manifested a partial response (>30% tumor reduction). Among the 22 lesions with a complete response, 5 (22%) developed a subsequent local relapse at the site of DaRT implantation at a median time of 4.9 months (range, 2.43-5.52 months). The 1-year local progression-free survival probability at the implanted site was 44% overall (confidence interval [CI], 20.3%-64.3%) and 60% (95% CI, 28.61%-81.35%) for complete responders. Overall survival rates at 12 months post-DaRT implantation were 75% (95% CI, 46.14%-89.99%) among all patients and 93% (95% CI, 59.08%-98.96%) among complete responders. Alpha-emitter brachytherapy using DaRT achieved significant tumor responses without grade 3 or higher toxicities observed. Longer follow-up observations and larger studies are underway to validate these findings.

1 October 2006 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Closed access
APAron Popovtzer
Aron Popovtzer
TSThomas Shpitzer
Thomas Shpitzer
GBGideon Bahar
Gideon Bahar
RFRaphael Feinmesser
Raphael Feinmesser
KSKarol Segal
Karol Segal

17 May 2006 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Closed access
KSKarl Segal
Karl Segal
TSThomas Shpitzer
Thomas Shpitzer
AHAlain Hazan
Alain Hazan
GBGideon Bachar
Gideon Bachar
GMGideon Marshak
Gideon Marshak
APAron Popovtzer
Aron Popovtzer

24 August 2016 in Head & Neck
Verified
Journal Article
Closed access
PDF file
APAron Popovtzer
Aron Popovtzer
HBHanna Burnstein
Hanna Burnstein
SSSalomon Stemmer
Salomon Stemmer
DLDror Limon
Dror Limon
OHOhad Hili
Ohad Hili
JSJacob Shvero
Jacob Shvero

24 November 2019 in Head & Neck
Verified
Journal Article
Closed access
PDF file
AMAssaf Moore
Assaf Moore
YBYael Bar
Yael Bar
CMCorinne Maurice‐Dror
Corinne Maurice‐Dror
IOInna Ospovat
Inna Ospovat
MSMichal Sarfaty
Michal Sarfaty
APAron Popovtzer
Aron Popovtzer

25 June 2021 in Medicine
Verified
Journal Article
Open access
AMAssaf Moore
Assaf Moore
YBYael Bar
Yael Bar
CMCorinne Maurice-Dror
Corinne Maurice-Dror
IFInbar Finkel
Inbar Finkel
HGHadar Goldvaser
Hadar Goldvaser
APAron Popovtzer
Aron Popovtzer
Radioiodine-refractory thyroid cancers (IRTCs) are uncommon and have a poor prognosis. Treatment options for radioiodine-refractory and anaplastic tumors (ATCs) are limited. Although the genomic landscape of thyroid cancer has been studied, there is little evidence on whether next-generation sequencing (NGS) findings translate to tumor control. We analyzed all patients with IRTC and ATC who underwent commercially available NGS in 3 cancer centers. Twenty-two patients were identified, 16 patients with IRTCs and 6 patients with ATCs. Eighteen (82%) had targetable findings in NGS, nine patients were treated accordingly. Median progression-free survival for targeted treatment was 50 months [95% confidence interval (CI95%) 9.8–66.6] and2 months (CI95% 0.2–16.5) for IRTC and ATC, respectively. Of 4 patients who achieved durable responses of 7 to 50 months, 2 are ongoing. The estimated median OS of IRTC receiving targeted treatment was not reached (CI95% 89.7–111.4 months) and was 77.8 months (CI95% 52.5–114.6) for patients treated conventionally (P = .3). NGS may detect clinically significant genetic alterations and benefit patients with advanced thyroid cancers.